EGFR and non-small cell lung carcinoma: Evidence suggests that local treatment improves survival in oligometastatic NSCLC, as demonstrated in the SINDAS trial, which included patients with EGFR-mutated NSCLC [1]; the SABR-COMET trial [2], which included 18 patients with NSCLC; and two small clinical trials on consolidative local treatment in NSCLC [3,4].